TCGA-22-1017-01A-01R-A96U-41
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.370
- INTERFERON_ALPHA_RESPONSE+0.350
- OXIDATIVE_PHOSPHORYLATION+0.330
- INFLAMMATORY_RESPONSE+0.310
- MYC_TARGETS_V2+0.300
- COMPLEMENT+0.290
- ALLOGRAFT_REJECTION+0.240
- IL6_JAK_STAT3_SIGNALING+0.240
- IL2_STAT5_SIGNALING+0.230
- SPERMATOGENESIS+0.220
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.480
- HEDGEHOG_SIGNALING-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- APICAL_JUNCTION-0.270
- APICAL_SURFACE-0.250
- MYOGENESIS-0.240
- NOTCH_SIGNALING-0.180
- UV_RESPONSE_DN-0.170
- DNA_REPAIR-0.150
- CHOLESTEROL_HOMEOSTASIS-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a3b44031-71ef-476f-a8bd-3694226ce026 | — | — | 0.768 |
| 2 | TCGA-22-1017-01A-01R-0692-07 | — | cohortA1 | 0.735 |
| 3 | SRR9879275 | — | cohortA1 | 0.730 |
| 4 | SRR8518156 | — | D | 0.730 |
| 5 | C3L-04757 | — | cohortA1 | 0.724 |
| 6 | SRR8518312 | — | D | 0.722 |
| 7 | a0fad25f-74d8-42f1-8e47-4d56c091e000 | — | — | 0.722 |
| 8 | GSM6454734 | — | D | 0.721 |
| 9 | TCGA-05-5420-01A-01R-1628-07 | — | cohortA1 | 0.720 |
| 10 | MNG784 | — | — | 0.718 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.080 | Inavolisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |